Tag ALS

9 Mar

NeuroGenesis and Hadassah Report Positive NF-L Biomarker Results from a Phase 2 Study in Progressive Multiple Sclerosis Treated with NG-01 Cells Therapy

NeuroGenesis, a clinical-stage biopharmaceutical company advancing innovative cell therapies to combat myelin-related neurodegenerative diseases, and Hadassah Medical Centre announced last week positive results from a placebo-controlled Phase 2 clinical trial assessing the impact of NG-01 autologous proprietary subpopulation of bone marrow cells on the expression levels of NF-L, a commonly-used biomarker for multiple sclerosis (MS) […]

Hadassah and Neurogenesis announce results from Phase 2 MS Study

A Phase 2 study at Hadassah Hospital Ein Kerem has revealed significant clinical improvements in patients with progressive multiple sclerosis (MS) after being treated with NG-01 stem cells developed by NeuroGenesis, a clinical-stage biopharmaceutical company advancing innovative cell therapies to combat neurodegenerative diseases. The 14-month randomized, double blind, placebo-controlled study, comprised of 48 patients, was led by Prof. […]

A Culture of Research

From developing a melanoma vaccine to working on controlling diabetes, Hadassah’s multidisciplinary, collaborative approach is resulting in medical breakthroughs and innovations. Tens of thousands bless Travelan, the over-the-counter natural health product that helps prevent traveler’s diarrhea. The ultrasound device PainShield has wrought a revolution in healing chronic wounds. And PerioChip, inserted between tooth and gum, […]

GET IN TOUCH

USEFUL LINKS

About Us
Our Team
Annual Report
Terms and Conditions